ABSTRACT
The antiviral section for the 7th edition of Kucer’s Use of Antibiotics has provided challenges. There are some reasons for this, including the rapid development pace of drugs for treatment of hepatitis C virus infection and the new interest in drugs for respiratory infections. With HIV infection, the development of a number of long-acting formulations and fixed-dose combination antiretroviral pills and discoveries regarding treatment as prevention (Cohen et al., 2016) have added complexity to our knowledge and stimulated rapid investigational drug development.
